Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second ...

Truist keeps a Buy rating and $46 price target on Edgewise Therapeutics (EWTX) following the company’s updates from Phase 2 EDG-7500 trial in ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

Cytokinetics announced FDA approval of MYQORZO™ (aficamten) to treat adults with symptomatic obstructive hypertrophic ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.